News
ALVOW
0.2600
0.00%
0.0000
Weekly Report: what happened at ALVO last week (0420-0424)?
Weekly Report · 1d ago
Alvotech updates financial calendar ahead of quarterly results webcast
PUBT · 4d ago
Alvotech publishes 2025 annual report
PUBT · 5d ago
Weekly Report: what happened at ALVO last week (0413-0417)?
Weekly Report · 04/20 09:51
Johnson & Johnson: Why I See Downside Ahead
Seeking Alpha · 04/17 14:42
Weekly Report: what happened at ALVO last week (0406-0410)?
Weekly Report · 04/13 09:53
Alvotech: Improving Fundamentals Signal A Potential Bottom For This Biosimilar Player
Seeking Alpha · 04/10 09:49
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 04/07 21:05
Mach Natural Resources, Mesoblast And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Benzinga · 04/07 12:02
Weekly Report: what happened at ALVO last week (0330-0403)?
Weekly Report · 04/06 09:53
Alvotech Earnings Call: Growth Momentum Meets FDA Risk
TipRanks · 04/02 00:06
Why nCino Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Benzinga · 04/01 09:27
Alvotech announces availability of fiscal 2025 Form 20-F annual report
Reuters · 03/31 00:03
Alvotech announces publication of FY 2025 annual report
Reuters · 03/30 23:55
Alvotech publishes 2025 annual report
Reuters · 03/30 23:55
Alvotech Files Annual Report with the SEC
Barchart · 03/30 18:55
Alvotech Publishes 2025 Annual Report
Barchart · 03/30 18:55
Weekly Report: what happened at ALVO last week (0323-0327)?
Weekly Report · 03/30 09:54
Alvotech Price Target Cut to $6.00/Share From $10.00 by UBS
Dow Jones · 03/24 14:46
Alvotech Is Maintained at Buy by UBS
Dow Jones · 03/24 14:46
More
Webull provides a variety of real-time ALVOW stock news. You can receive the latest news about Alvotech through multiple platforms. This information may help you make smarter investment decisions.
About ALVOW
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.